Finasteride for BPH, Prostatitis, and Prostate Cancer | скачать в хорошем качестве

Finasteride for BPH, Prostatitis, and Prostate Cancer |

Donate to PCRI: https://pcri.org/donate/ For more information, visit https://pcri.org 0:20 What is Finasteride? 1:23 What effect does Finasteride have on PSA levels? 3:06 How does Finasteride affect PSA levels for patients on active surveillance? 4:53 Is there any reason a patient should avoid Finasteride? 6:12 Is there a major alternative medicine to Finasteride? 6:53 How long to Finasteride's side effects last? 7:45 What other side effects are associated with Finasteride? 8:12 Does the dosage of Finasteride change based on his intended usage? 8:28 How does Finasteride compare to other urinary flow medication's? 9:27 What is a black box warning and how does it apply to Finasteride? 11:20 Is Finasteride considered a hormone therapy treatment? 12:40 How long does a typical course of finasteride last? 13:14 Alex's conclusions 14:25 If you need more help Don't know your stage? Take the quiz: visit http://www.prostatecancerstaging.org To learn more about prostate cancer, visit http://www.pcri.org Sign up for our newsletter here to receive the latest updates on prostate cancer and the PCRI: https://pcri.org/join Who we are: The Prostate Cancer Research Institute (PCRI) is a 501(c)(3) not-for-profit organization that is dedicated to helping you research your treatment options. We understand that you have many questions, and we can help you find the answers that are specific to your case. All of our resources are designed by a multidisciplinary team of advocates and expert physicians for patients. We believe that by educating yourself about the disease, you will have more productive interactions with your medical professionals and receive better-individualized care. Feel free to explore our website at pcri.org or contact our free helpline with any questions that you have at pcri.org/helpline. Our Federal Tax ID # is 95-4617875 and qualifies for maximum charitable gift deductions by individual donors.